CMS
CMS negotiated prices for 10 drugs costly to Medicare
CMS successfully negotiated prices on costly drugs for diabetes, cancer, heart failure, and other indications. New pricing will take effect January 1, 2026 for patients with Medicare Part D prescription drug coverage. Had new prices had been in effect last year, Medicare would have saved an estimated $6 billion, or approximately 22%.
About nine million people with Medicare use at least one of the 10 drugs selected for negotiation: Eliquis, Enbrel, Entresto, Farxiga, Imbruvica, Januvia, Jardiance, Stelara, Xarelto, and various insulins.
In 2025, all Medicare Part D patients will have a $2,000 out-of-pocket cap on prescription drug costs. Then, in 2026, patients with Medicare prescription drug coverage are expected to see aggregated estimated savings of $1.5 billion in personal out-of-pocket costs.
Source:
(2024, August 15). CMS.gov. Negotiating for Lower Drug Prices Works, Saves Billions. [News release]. https://www.cms.gov/newsroom/press-releases/negotiating-lower-drug-prices-works-saves-billions